Edition:
United States

Charles River Laboratories International Inc (CRL.N)

CRL.N on New York Stock Exchange

130.73USD
19 Aug 2019
Change (% chg)

$0.89 (+0.69%)
Prev Close
$129.84
Open
$131.73
Day's High
$131.94
Day's Low
$130.57
Volume
43,604
Avg. Vol
93,776
52-wk High
$148.97
52-wk Low
$103.00

Latest Key Developments (Source: Significant Developments)

Charles River Laboratories Reports Q2 EPS Of $0.88
Wednesday, 31 Jul 2019 07:00am EDT 

July 31 (Reuters) - Charles River Laboratories International Inc ::CHARLES RIVER LABORATORIES ANNOUNCES SECOND-QUARTER 2019 RESULTS.Q2 NON-GAAP EARNINGS PER SHARE $1.63.Q2 GAAP EARNINGS PER SHARE $0.88.Q2 REVENUE $657.6 MILLION VERSUS REFINITIV IBES ESTIMATE OF $662.5 MILLION.Q2 EARNINGS PER SHARE ESTIMATE $1.55 -- REFINITIV IBES DATA.UPDATES 2019 GUIDANCE.NARROWING FY GUIDANCE RANGES FOR BOTH REPORTED AND ORGANIC REVENUE GROWTH..FOREIGN EXCHANGE IS NOW EXPECTED TO REDUCE REPORTED REVENUE GROWTH BY 1% TO 1.5% IN 2019..REDUCING ITS GAAP EARNINGS PER SHARE GUIDANCE BY $0.10 FOR FY.NON-GAAP EARNINGS PER SHARE GUIDANCE IS BEING INCREASED BY $0.05 FOR FY.REAFFIRMING FY FREE CASH FLOW GUIDANCE..SEES FY 2019 GAAP EPS ESTIMATE$4.65-$4.80.SEES FY 2019 NON-GAAP EPS ESTIMATE $6.45 - $6.60.SEES FY 2019 REVENUE GROWTH, REPORTED 16% TO 17%.FY2019 EARNINGS PER SHARE VIEW $6.47 -- REFINITIV IBES DATA.FY2019 REVENUE VIEW $2.65 BILLION -- REFINITIV IBES DATA.  Full Article

Charles River Laboratories Invests In Resero Analytics
Thursday, 16 May 2019 08:00am EDT 

May 16 (Reuters) - Charles River Laboratories International Inc ::CHARLES RIVER LABORATORIES INVESTS IN RESERO ANALYTICS™.CHARLES RIVER LABORATORIES INTERNATIONAL - INVESTED IN RESERO ANALYTICS, A SOFTWARE CO FOCUSED ON PROVIDING SOLUTIONS TO BIOPHARMACEUTICAL INDUSTRY.  Full Article

Charles River Laboratories Q1 GAAP Earnings Per Share $1.11
Tuesday, 7 May 2019 07:00am EDT 

Charles River Laboratories International Inc ::ANNOUNCES FIRST-QUARTER 2019 RESULTS.Q1 NON-GAAP EARNINGS PER SHARE $1.40.Q1 GAAP EARNINGS PER SHARE $1.11.Q1 REVENUE $604.6 MILLION VERSUS REFINITIV IBES ESTIMATE OF $595.7 MILLION.SEES FY 2019 GAAP EARNINGS PER SHARE $4.75 TO $4.90 INCLUDING ITEMS.Q1 EARNINGS PER SHARE ESTIMATE $1.38 -- REFINITIV IBES DATA.INTERNATIONAL INC - REAFFIRMS 2019 GUIDANCE INCLUDING CITOXLAB.  Full Article

Charles River Laboratories International Says Has Completed Previously Announced Acquisition Of Citoxlab For EUR 448 Mln In Cash
Monday, 29 Apr 2019 07:00am EDT 

April 29 (Reuters) - Charles River Laboratories International Inc ::CHARLES RIVER LABORATORIES INTERNATIONAL SAYS HAS COMPLETED PREVIOUSLY ANNOUNCED ACQUISITION OF CITOXLAB FOR EUR 448 MILLION IN CASH.  Full Article

Charles River Laboratories International Inc Says CEO James C. Foster's 2018 Total Compensation Was $14.5 Million
Thursday, 4 Apr 2019 09:58am EDT 

April 4 (Reuters) - Charles River Laboratories International Inc ::CHARLES RIVER LABORATORIES INTERNATIONAL INC SAYS CEO JAMES C. FOSTER'S 2018 TOTAL COMPENSATION WAS $14.5 MILLION VERSUS $12.6 MILLION IN 2017 – SEC FILING.CHARLES RIVER LABORATORIES -FOR 2018, RATIO OF ANNUAL TOTAL COMPENSATION OF CEO TO MEDIAN OF ANNUAL TOTAL COMPENSATION OF ALL EMPLOYEES WAS 320 TO 1.  Full Article

Charles River Laboratories Q4 GAAP Loss Per Share $0.63
Tuesday, 13 Feb 2018 07:01am EST 

Feb 13 (Reuters) - Charles River Laboratories International Inc ::CHARLES RIVER LABORATORIES ANNOUNCES FOURTH-QUARTER AND FULL-YEAR 2017 RESULTS FROM CONTINUING OPERATIONS AND PROVIDES 2018 GUIDANCE.Q4 NON-GAAP EARNINGS PER SHARE $1.40.Q4 GAAP LOSS PER SHARE $0.63.Q4 REVENUE ROSE 2.5 PERCENT TO $478.5 MILLION.Q4 EARNINGS PER SHARE VIEW $1.25, REVENUE VIEW $474.6 MILLION -- THOMSON REUTERS I/B/E/S.CHARLES RIVER LABORATORIES SEES 2018 NON-GAAP EARNINGS PER SHARE FROM CONTINUING OPERATIONS $5.42 - $5.57.CHARLES RIVER LABORATORIES SEES 2018 GAAP EARNINGS PER SHARE FROM CONTINUING OPERATIONS $4.71 - $4.86.SEES 2018 REVENUE GROWTH, REPORTED, FROM CONTINUING OPERATIONS OF 7.2% TO 8.2%.FY2018 EARNINGS PER SHARE VIEW $5.58, REVENUE VIEW $1.99 BILLION -- THOMSON REUTERS I/B/E/S.CHARLES RIVER LABORATORIES - EXCLUDING MPI, 2018 EPS EXPECTED TO BENEFIT FROM HIGHER REVENUE, MODEST OPERATING. MARGIN IMPROVEMENT.CHARLES RIVER LABORATORIES - 2018 EARNINGS PER SHARE GUIDANCE INCLUDES GAIN OF $0.14 ON VENTURE CAPITAL INVESTMENTS.CHARLES RIVER LABORATORIES - 2018 EARNINGS PER SHARE GUIDANCE ALSO INCLUDES GAIN OF $0.14 FOR EXCESS TAX BENEFIT ASSOCIATED WITH STOCK COMPENSATION.CHARLES RIVER LABORATORIES SEES 2018 NON-GAAP EARNINGS PER SHARE INCLUDING MPI $5.67 - $5.82.  Full Article

Charles River Laboratories To Buy MPI Research For About $800 Mln
Tuesday, 13 Feb 2018 07:00am EST 

Feb 13 (Reuters) - Charles River Laboratories International Inc ::CHARLES RIVER LABORATORIES TO ACQUIRE MPI RESEARCH.CHARLES RIVER LABORATORIES INTERNATIONAL INC - DEAL FOR APPROXIMATELY $800 MILLION.CHARLES RIVER LABORATORIES - DEAL EXPECTED TO BE ACCRETIVE TO NON-GAAP EPS BY APPROXIMATELY $0.25 IN 2018 AND APPROXIMATELY $0.60 IN 2019​.CHARLES RIVER LABORATORIES INTERNATIONAL INC - ‍FOR 2017, MPI IS EXPECTED TO GENERATE ANNUAL REVENUE OF APPROXIMATELY $240 MILLION​.CHARLES RIVER LABORATORIES INTERNATIONAL - ‍EXPECTS TO GENERATE OPERATIONAL SYNERGIES AS RESULT OF DEAL, WITH BENEFITS TOTALING $13 TO $16 MILLION BY END OF 2019​.CHARLES RIVER LABORATORIES - DEAL EXPECTED TO ADD $170 TO $190 MILLION TO CHARLES RIVER'S 2018 CONSOLIDATED REVENUE BASED ON ANTICIPATED TIMING OF CLOSE​.CHARLES RIVER LABORATORIES INTERNATIONAL - ‍ACQUISITION & ASSOCIATED FEES ARE EXPECTED TO BE FINANCED THROUGH AN EXPANSION OF CO'S CREDIT FACILITY & CASH​.CHARLES RIVER LABORATORIES INTERNATIONAL INC - ‍COMPANY IS EVALUATING FIXED-RATE DEBT FINANCING ALTERNATIVES WHICH COULD BE USED TO FINANCE ACQUISITION​.CHARLES RIVER LABORATORIES INTERNATIONAL INC - ‍ACQUISITION IS EXPECTED TO ADD $260 TO $280 MILLION TO 2019 CONSOLIDATED REVENUE​.CHARLES RIVER LABORATORIES INTERNATIONAL INC - DEAL,ASSOCIATED FEES EXPECTED TO BE FINANCED THROUGH EXPANSION OF CHARLES RIVER'S CREDIT FACILITY, CASH​.  Full Article

Charles River Laboratories Acquires KWS Biotest for GBP 15 Mln
Thursday, 11 Jan 2018 07:00am EST 

Jan 11 (Reuters) - Charles River Laboratories International Inc ::CHARLES RIVER LABORATORIES ACQUIRES KWS BIOTEST.CHARLES RIVER LABORATORIES ACQUIRES KWS BIOTEST.CHARLES RIVER LABORATORIES INTERNATIONAL INC - PURCHASE PRICE WAS APPROXIMATELY £15 MILLION IN CASH.CHARLES RIVER LABORATORIES INTERNATIONAL INC - ‍ TRANSACTION INCLUDES A POTENTIAL ADDITIONAL PAYMENT OF UP TO £3 MILLION BASED ON FUTURE PERFORMANCE​.CHARLES RIVER LABORATORIES INTERNATIONAL INC - TRANSACTION IS NOT EXPECTED TO BE MATERIAL TO 2018 GAAP OR NON-GAAP RESULTS FROM OPERATIONS.CHARLES RIVER LABORATORIES INTERNATIONAL INC - TRANSACTION IS NOT EXPECTED TO BE MATERIAL TO 2018 GAAP OR NON-GAAP RESULTS FROM OPERATIONS.  Full Article

Charles River Laboratories Says New Tax Legislation Expected To Be Effectively Neutral To Co's GAAP, Non-GAAP EPS In 2018
Tuesday, 9 Jan 2018 08:19am EST 

Jan 9 (Reuters) - Charles River Laboratories International Inc ::CHARLES RIVER LABORATORIES SAYS NEW TAX LEGISLATION EXPECTED TO BE EFFECTIVELY NEUTRAL TO CO'S GAAP AND NON-GAAP EPS IN 2018 - SEC FILING.  Full Article

Charles River Laboratories reports Q3 non-GAAP EPS of $1.30
Thursday, 9 Nov 2017 07:00am EST 

Nov 9 (Reuters) - Charles River Laboratories International Inc ::Updates 2017 guidance​.Announces third-quarter 2017 results from continuing operations.Q3 non-GAAP earnings per share $1.30.Q3 GAAP earnings per share $1.09.Q3 revenue $464.2 million versus I/B/E/S view $458.7 million.Q3 earnings per share view $1.22 -- Thomson Reuters I/B/E/S.Sees ‍2017 revenue growth, reported 9.75 percent - 10.5 percent​.Sees ‍2017 non-GAAP EPS estimate $5.08 - $5.18​.Sees ‍2017 GAAP EPS estimate $3.95 - $4.05​.FY2017 earnings per share view $5.10, revenue view $1.85 billion -- Thomson Reuters I/B/E/S.  Full Article

FOCUS-Blue-blooded crabs at heart of pharma dispute on drug testing

ZURICH, Aug 1 If you've received a vaccination, hip replacement or chemotherapy without suffering toxic shock, chances are you've benefited from a vast bloodletting of horseshoe crabs.